Bacterial Infection: Clinical Trials

12 trials for Bacterial Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 terminated, 1 withdrawn. 12 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 112Completed 10, Terminated 1, Withdrawn 1
Phase 23Completed 2, Withdrawn 1

Follow Bacterial Infection: new trials by email Literature Review of Bacterial Infection trials Research Report on Bacterial Infection

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of Intravenous Apramycin in Adults
Apramycin (EBL-1003) - Bacterial Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)162023-06-162025-03-06
Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
Ertapenem, Placebo, WCK 6777 - Bacterial Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)542023-04-192025-01-20
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
AZACTAM, Ceftazidime-Avibactam - Bacterial Infection
Phase 1 / Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)482019-07-092022-06-07
Intravenous Fosfomycin Pharmacokinetics Study
Fosfomycin disodium - Bacterial Infection, Multiple-drug Resistance
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)392019-06-272023-10-23
Pharmacokinetics and Safety of Solithromycin in Adolescents and Children
solithromycin - Bacterial Infection
Phase 1CompletedMelinta Therapeutics, Inc.842015-01-012017-06-09
Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg
TR-701 FA - Bacterial Infection
Phase 1CompletedTrius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)202010-12-082019-11-15
Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients
TR-701 FA - Bacterial Infection
Phase 1CompletedTrius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)202010-06-022018-12-07
Cerebral Antibiotics Distribution After Acute Brain Injury
cefotaxime, Metronidazole, Ciprofloxacin - Bacterial Infection, Brain Injury
Phase 1CompletedPoitiers University Hospital182009-09-012016-10-11
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients
human lactoferrin (hLF1-11) - Fungal Infection, Bacterial Infection
Phase 1 / Phase 2WithdrawnAM-Pharma2008-11-012015-06-30
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416
GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg) - Bacterial Infection, Infections, Bacterial
Phase 1TerminatedGlaxoSmithKline962007-06-012017-01-20
Effect of Chlorhexidine Cleansing on Skin Flora of Newborns in Nepal
skin cleansing with chlorhexidine (0.25%, 0.5%, 1%) - Bacterial Infection
Phase 1 / Phase 2CompletedJohns Hopkins Bloomberg School of Public Health2862006-01-012010-04-05
An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates
Azithromycin - Ureaplasma, Bacterial Infection
Phase 1CompletedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)162005-09-012008-09-26

Narrower conditions

Bacterial Infections (12)  ·  Brain Injuries (1)  ·  Infections (1)  ·  Mycoses (1)  ·  Neutropenia (1)

Broader conditions

Bacterial Infections and Mycoses (12)  ·  Infections (11)  ·  Agranulocytosis (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Craniocerebral Trauma (1)  ·  Cytopenia (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Leukocyte Disorders (1)  ·  Leukopenia (1)  ·  Nervous System Diseases (1)  ·  Trauma, Nervous System (1)  ·  Wounds and Injuries (1)

Interventions

Azithromycin (1)  ·  Aztreonam (1)  ·  Cefotaxime (1)  ·  Chlorhexidine (1)  ·  Ciprofloxacin (1)  ·  Ertapenem (1)  ·  Ketoconazole (1)  ·  Metronidazole (1)  ·  apramycin (1)  ·  avibactam, ceftazidime drug combination (1)  ·  solithromycin (1)  ·  zidebactam (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2)  ·  AM-Pharma (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  GlaxoSmithKline (1)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  Melinta Therapeutics, Inc. (1)  ·  Poitiers University Hospital (1)

Countries

United States (7)  ·  Australia (1)  ·  Bulgaria (1)  ·  France (1)  ·  Nepal (1)  ·  Netherlands (1)

Top investigators

David Edwards, Pharm.D. (1)  ·  David Nicolau, PharmD (1)  ·  Elias Tessema, M.D. (1)  ·  Jacob Aranda, M.D., Ph.D. (1)  ·  Luke C Mullany, PhD (1)  ·  Michael Cohen-Wolkowiez, MD (1)  ·  Peter J Donnelly, PhD (1)

Results publications

PMID 22330925, PMID 29891609, PMID 31318840, PMID 39772650, PMID 42809435

NIH funding

5UM1AI104681-09 (1), R01HD044004 (1)